The Prognostic Value of Cell-Free DNA in Advanced Non-Small-Cell Lung Cancer

Abstract

Background: Cell-free DNA (cfDNA) holds promise as a tumor marker of clinical importance. We aimed to investi gate the prognostic value of baseline cfDNA in non small-cell lung cancer (NSCLC). Material and Methods: During a three-year period, patients with newly diagnosed, previously untreated advanced NSCLC were included in a consecu tive, prospective marker-trial. Plasma was isolated from a pre-treatment peripheral blood sample and the level of total cfDNA was measured by an in-house assay qPCR-method. The treatment comprised carboplatin (AUC 5) intravenously day 1), and vinorelbine (30 mg/m 2 intravenously day 1 and 60 mg/m 2 perorally day 8) q3w for a maximum of six cycles. The primary end-point was overall survival (OS). Secondary end-points were progression free survival (PFS) and over all response rate (ORR). Results: 245 patients were included and received a minimum of 1 cycle of chemotherapy (me dian 4). The median OS was 8.9 months, the median PFS by intention to treat 5.4 months and the ORR was 25%. The patients were divided into four groups based on quartiles of cfDNA and subsequently dichotomized by the 75th percen tile revealing a significantly worse prognosis for patients in the upper 75th percentile (median OS 4.9 months) com pared to patients with lower levels (10.0 months) (HR 2.1, 95%CI 1.4 - 3.1, p < 0.0001). A multivariate analysis con firmed the independent prognostic value of cfDNA. A subgroup analysis of patients with high cfDNA and poor per formance status (PS = 2) identified a group of patients with even worse prognosis (median OS 2.0 versus 9.1 months, HR 3.6, 95%CI 1.4 - 9.2, p < 0.0001). Similar and significant results were found when comparing level of cfDNA and PFS. Conclusions: High pre-treatment level of cfDNA seems to have a strong prognostic impact in patients with newly diagnosed advanced NSCLC. Combined with PS it identifies a patient group with minimal or no benefit of chemother apy.